BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers (Basel) 2021;13:4778. [PMID: 34638263 DOI: 10.3390/cancers13194778] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Dorraji E, Borgen E, Segura-peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA. Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. Cancers 2022;14:4859. [DOI: 10.3390/cancers14194859] [Reference Citation Analysis]
2 Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers (Basel) 2022;14:4543. [PMID: 36139701 DOI: 10.3390/cancers14184543] [Reference Citation Analysis]
3 Hayat A, Carter E, King H, Ors A, Doe A, Teijeiro S, Charrot S, Godinho S, Cutillas P, Mohammed H, Grose R, Ficz G. Low HER2 enables dedifferentiation and transformation of normal breast epithelial cells via chromatin opening.. [DOI: 10.1101/2022.09.06.506760] [Reference Citation Analysis]
4 Lucas LM, Cullum RL, Markham JA, Woggerman JN, Dwivedi V, Mohamedelhassan RH, Cook LJ, Kelley CM, Knerr EL, Kaufmann DP, Jacobi MA, Taylor DC, Rael CC, Waits DS, Ghosh TM, Halanych KM, Gupta RB, Riese DJ. ERBB4 Mutant Alleles May Drive BRAF WT Melanomas.. [DOI: 10.1101/2022.06.21.22276707] [Reference Citation Analysis]
5 Jiang H, Sun J, Liu F, Wu X, Wen Z. An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer. Front Genet 2022;13:895200. [DOI: 10.3389/fgene.2022.895200] [Reference Citation Analysis]
6 Lucas L, Cullum R, Dwivedi V, Markham J, Woggerman J, Kelley C, Knerr E, Cook L, Lucas H, Waits D, Ghosh T, Halanych K, Gupta R, Riese D. ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines.. [DOI: 10.1101/2022.06.20.22276663] [Reference Citation Analysis]
7 Lin K, Baritaki S, Vivarelli S, Falzone L, Scalisi A, Libra M, Bonavida B. The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. Antioxidants (Basel) 2022;11:1195. [PMID: 35740092 DOI: 10.3390/antiox11061195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lyu C, Ye Y, Weigel RJ, Chen S. Blocking Gi/o-Coupled Signaling Eradicates Cancer Stem Cells and Sensitizes Breast Tumors to HER2-Targeted Therapies to Inhibit Tumor Relapse. Cancers (Basel) 2022;14:1719. [PMID: 35406489 DOI: 10.3390/cancers14071719] [Reference Citation Analysis]
9 Lyu C, Ye Y, Weigel RJ, Chen S. Blocking Gi/o-coupled signaling eradicates cancer stem cells and sensitizes breast tumors to HER2-targeted therapies to inhibit tumor relapse.. [DOI: 10.1101/2022.02.05.479272] [Reference Citation Analysis]
10 Mir MA, Naik AQ. Breast cancer stem cells and their role in tumor microenvironment. Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies 2022. [DOI: 10.1016/b978-0-443-18696-7.00005-1] [Reference Citation Analysis]